11-18704529-T-C
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The ENST00000280734.3(TMEM86A):c.*2520T>C variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000131 in 1,548,686 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000053 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00014 ( 0 hom. )
Consequence
TMEM86A
ENST00000280734.3 3_prime_UTR
ENST00000280734.3 3_prime_UTR
Scores
1
15
Clinical Significance
Conservation
PhyloP100: 1.22
Genes affected
IGSF22 (HGNC:26750): (immunoglobulin superfamily member 22)
TMEM86A (HGNC:26890): (transmembrane protein 86A) Predicted to enable alkenylglycerophosphocholine hydrolase activity and alkenylglycerophosphoethanolamine hydrolase activity. Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.16289163).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
IGSF22 | NM_173588.4 | c.3920A>G | p.Asp1307Gly | missense_variant | 23/23 | ENST00000513874.6 | NP_775859.4 | |
TMEM86A | NM_153347.3 | c.*2520T>C | 3_prime_UTR_variant | 3/3 | ENST00000280734.3 | NP_699178.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
IGSF22 | ENST00000513874.6 | c.3920A>G | p.Asp1307Gly | missense_variant | 23/23 | 5 | NM_173588.4 | ENSP00000421191 | P1 | |
TMEM86A | ENST00000280734.3 | c.*2520T>C | 3_prime_UTR_variant | 3/3 | 1 | NM_153347.3 | ENSP00000280734 | P1 | ||
IGSF22 | ENST00000319338.6 | c.*816A>G | 3_prime_UTR_variant, NMD_transcript_variant | 21/21 | 2 | ENSP00000322422 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152072Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
8
AN:
152072
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000911 AC: 14AN: 153656Hom.: 0 AF XY: 0.0000858 AC XY: 7AN XY: 81574
GnomAD3 exomes
AF:
AC:
14
AN:
153656
Hom.:
AF XY:
AC XY:
7
AN XY:
81574
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000140 AC: 195AN: 1396614Hom.: 0 Cov.: 28 AF XY: 0.000139 AC XY: 96AN XY: 689072
GnomAD4 exome
AF:
AC:
195
AN:
1396614
Hom.:
Cov.:
28
AF XY:
AC XY:
96
AN XY:
689072
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000526 AC: 8AN: 152072Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74284
GnomAD4 genome
AF:
AC:
8
AN:
152072
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74284
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
2
ExAC
AF:
AC:
2
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 23, 2021 | The c.3920A>G (p.D1307G) alteration is located in exon 23 (coding exon 22) of the IGSF22 gene. This alteration results from a A to G substitution at nucleotide position 3920, causing the aspartic acid (D) at amino acid position 1307 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
D
LIST_S2
Benign
T
M_CAP
Benign
T
MetaRNN
Benign
T
MetaSVM
Benign
T
MutationTaster
Benign
N;D
PrimateAI
Benign
T
PROVEAN
Benign
N
REVEL
Benign
Sift
Benign
D
Sift4G
Benign
T
Vest4
MutPred
Gain of MoRF binding (P = 0.0833);
MVP
MPC
ClinPred
T
GERP RS
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at